Navigation Links
Maturitas publishes a clinical guide on lichen sclerosus
Date:2/14/2013

Amsterdam, February 14, 2013 Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of a clinical guide by the European Menopause and Andropause Society (EMAS) in its journal Maturitas on lichen sclerosus with summary recommendations.

Vulvar lichen sclerosus (LS) is a chronic inflammatory disease which affects genital labial, perineal and perianal areas, producing significant discomfort and psychological distress. The purpose of this clinical guide is to provide advice on early recognition and treatment to prevent delay in management. Women presenting with vulvar pruritus and pain should be examined by a health professional with expertise in vulvar skin disorders. First line treatment is a topical corticosteroid cream and calcineurin inhibitors are second line. Surgical management such as vulvectomy or cryosurgery is reserved for women with malignancy or post-inflammatory sequelae.

These and other recommendations presented in the EMAS clinical guide are published in the article: 'EMAS clinical guide: Vulvar lichen sclerosus in peri and postmenopausal women by Faustino R. Prez-Lpez, Iuliana Ceausu, Herman Depypere, C. Tamer Erel, Irene Lambrinoudaki, Margaret Rees, Karin Schenck-Gustafsson, Florence Tremollieres, Yvonne T. van der Schouw and Tommaso Simoncini.' (doi:10.1016/j.maturitas.2012.12.006). The article appears in Maturitas Volume 74, Issue 3 (March 2013) published by Elsevier.


'/>"/>
Contact: Greyling Peoples
g.peoples@elsevier.com
31-204-853-323
Elsevier
Source:Eurekalert

Page: 1

Related medicine news :

1. Maturitas publishes clinical guide on low-dose vaginal estrogens for vaginal atrophy
2. Journal Maturitas publishes position statement on diet and health in midlife and beyond
3. SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples
4. Moffitt researcher publishes book on nutritional management of cancer treatment effects
5. Ear, Nose & Throat Journal publishes research on breakthrough treatment for tonsil stones
6. Natural Sciences Repository Publishes Chromatography and Acidic Compounds Resources
7. ASTRO publishes Safety is No Accident: A Framework for Quality Radiation Oncology and Care
8. Annals of Internal Medicine publishes new CDC recommendations on hepatitis C screening
9. Using an HRA to Comply with San Francisco's HCSO Requirements - Zane Benefits Publishes Information
10. Zane Benefits Publishes Information About Over-the-Counter (OTC) Medicines, Drugs and HRAs
11. Defined Contribution: A Healthcare Win for Brokers, Employers & Employees - Zane Benefits Publishes Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief ... advancements to physician colleagues, skilled nursing facility medical directors and other clinicians at ... of Wound Care." , "At many of these conferences we get to educate ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
Breaking Medicine Technology: